Euregen Biopharma Co. Ltd. has disclosed son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.
The U.S. Patent and Trademark Office (USPTO) published new enablement guidelines Jan. 10 to provide more consistency across technologies to ensure patent applications truly enable the breadth of their claims in keeping with the Supreme Court’s unanimous decision last year in Amgen Inc. v. Sanofi SA.
The first patenting from Mhealthcare Inc. describes a patient examination table or bed equipped with a variety of sensors, data from which may be analyzed with trained machine learning models to facilitate risk assessment and diagnosis of non-neurotypical developmental conditions such as autism in infants and young children by predicting cognitive, behavioral, social and developmental outcomes as early as the first three months of life. It is also claimed that the table may be used to diagnose epilepsy and Alzheimer’s disease.
Amygdala Neurosciences Inc. has described aldehyde dehydrogenase-2 (ALDH2) inhibitors reported to be useful for the treatment of anxiety disorder, binge eating disorder, alcoholism, and amphetamine, cocaine, nicotine and opioid dependence.
C4 Therapeutics Inc. has divulged proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently bound to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety through a linker.
Neuron23 Inc. has identified non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of neurological disorders.
Lumitex Inc. seeks patent protection for a phototherapeutic apparatus for treating inflammatory conditions, with a particular focus on treating acute respiratory distress syndrome.
RSS
